ReviewSpinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives
Section snippets
Functional significance of a cannabinoid transmitter system
The discovery of a G-protein-coupled cannabinoid receptor (Matsuda et al., 1990, Gerard et al., 1991) and identification of anandamide, the first isolated endogenous cannabinoid (Devane et al., 1992), established the existence of a cannabinoid transmitter system. The distribution of cannabinoid receptors in the central nervous system (Herkenham et al., 1991, Tsou et al., 1998) provides an anatomical basis for the profound effects of cannabinoids on behavior. Cannabinoid receptors are localized
Subtypes of cannabinoid receptors
Two cannabinoid receptor subtypes, CB1 and CB2, have been identified; CB1 is enriched in brain (Matsuda et al., 1990, Zimmer et al., 1999, Buckley et al., 2000) whereas CB2 is enriched in cells of the immune system (Munro et al., 1993, Lynn and Herkenham, 1994, Buckley et al., 2000). CB2 mRNA is found in cells associated with immune functions such as mast cells (Facci et al., 1995). The presence of CB1 (Hohmann et al., 1999a, Hohmann et al., 1999b, Ahluwalia et al., 2000, Ahluwalia et al., 2002
Cannabinoid receptor pharmacology
The development of competitive antagonists for CB1 (Rinaldi-Carmona et al., 1994) and CB2 (Rinaldi-Carmona et al., 1998) provide pharmacological tools for studying biological functions of cannabinoids. SR141716A binds to cannabinoid receptors in brain with high affinity (Kd=0.23 nM, Rinaldi-Carmona et al., 1994), but displays negligible affinity for CB2 (Ki(CB1 vs. CB2)=5.6 nM vs. >1 μM, Showalter et al., 1996). SR144528 (Rinaldi-Carmona et al., 1998) is a selective CB2 antagonist (Ki(CB1 vs.
Antinociceptive effects of cannabinoids
Cannabinoid antinociception is observed in behavioral studies employing different modalities of noxious stimulation including thermal, mechanical and chemical (see Walker et al., 2001 for review). The potency and efficacy of cannabinoid antinociception rivals that of morphine (Buxbaum, 1972, Bloom et al., 1977). However, cannabinoids also produce profound motor effects (e.g. immobility, catalepsy, Martin et al., 1991) that represent a confound for behavioral studies assessing motor responses to
Cannabinoid-induced suppression of nociceptive transmission
Electrophysiological and neurochemical studies provide convincing evidence that cannabinoids suppress nociceptive transmission in vivo (Hohmann et al., 1995, Hohmann et al., 1998, Hohmann et al., 1999b, Martin et al., 1996, Meng et al., 1998, Strangman and Walker, 1999, Tsou et al., 1996, Drew et al., 2000, Harris et al., 2000, Kelly and Chapman, 2001). Walker's laboratory first demonstrated that cannabinoids suppress noxious stimulus-evoked neuronal activity in nociceptive neurons in the
Acute pain
Antinociceptive effects of cannabinoids are mediated, in part, at the spinal level. Support for spinal mechanisms of cannabinoid analgesic action is derived from the ability of intrathecally administered cannabinoids to produce antinociception (Yaksh, 1981, Smith and Martin, 1992, Welch et al., 1995). The behavioral data are consistent with the ability of spinally administered cannabinoids to suppress noxious heat-evoked and afterdischarge firing in wide dynamic range neurons in rat lumbar
Localization of cannabinoid receptors in dorsal root ganglia and spinal cord
Cannabinoid receptors have been identified in rat spinal cord using autoradiographic (Herkenham et al., 1991, Hohmann and Herkenham, 1998, Hohmann et al., 1999a) and immunocytochemical (Tsou et al., 1998, Sañudo-Peña et al., 1999, Farquhar-Smith et al., 2000, Morisset et al., 2001, Salio et al., 2001, Salio et al., 2002b) techniques. It is important to note that localization studies employing antibodies raised against the N-terminal of the CB1 receptor protein reveal different patterns of
Summary
In the early 1990s, the neural mechanisms through which cannabinoids suppress pain were poorly understood, and it could not be stated with certainty that cannabinoids produced antinociception by suppressing nociceptive transmission rather than motor behavior. The discovery of cannabinoid receptors and endogenous cannabinoids set the stage for research demonstrating that: (1) cannabinoids suppress nociceptive processing, (2) this suppression involves supraspinal, spinal and peripheral
References (130)
- et al.
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
Neuroscience
(2000) - et al.
Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones
Neuroscience
(2002) - et al.
Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
Pain
(1988) - et al.
Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat
Eur. J. Pharmacol.
(2000) - et al.
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
Eur. J. Pharmacol.
(1998) - et al.
Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord
Brain Res.
(1990) - et al.
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor
Eur. J. Pharmacol.
(2000) Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats
Neuropharmacology
(2001)- et al.
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
Biochem. Pharmacol.
(1993) - et al.
Local anaesthesia prevents acute inflammatory changes in neuropeptide messenger RNA expression in rat dorsal root ganglia neurons
Neurosci. Lett.
(1994)
Cannabinoid CB(1) receptor expression in rat spinal cord
Mol. Cell. Neurosci.
Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors
Pain
The role of central and peripheral Cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain
Pain
Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation
Neuroscience
GABAergic synapses on mu-opioid receptor-expressing neurons in the superficial dorsal horn: an electron microscope study in the cat spinal cord
Neurosci. Lett.
The effect of a unilateral inflammation at the rat's ankle joint on the expression of preprotachykinin-A mRNA and preprosomatostatin mRNA in dorsal root ganglion cells-—a study using non-radioactive in situ hybridization
Brain Res.
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
Neurosci. Lett.
Regulation of cannabinoid and mu opioid receptor binding sites following neonatal capsaicin treatment
Neurosci. Lett.
Cannabinoid receptors undergo axonal flow in sensory nerves
Neuroscience
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study
Neuroscience
Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2
Life Sci.
Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2
Neurosci. Lett.
Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord
Brain Res.
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
Pain
The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder
Neurosci. Lett.
Central and peripheral expression of galanin in response to inflammation
Neuroscience
Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms
Pain
The mu-opioid receptor (MOR1) is mainly restricted to neurons that do not contain GABA or glycine in the superficial dorsal horn of the rat spinal cord
Neuroscience
Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat
Eur. J. Pharmacol.
Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors
Biochim. Biophys. Acta
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor
Eur. J. Pharmacol.
Nerve growth factor contributes to the up-regulation of growth-associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation
Neuroscience
The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats
Pain
Cannabinoid-induced antinociception is mediated by a spinal α2-noradrenergic mechanism
Brain Res.
Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry
Neuroscience
Inhibition of pain responses by activation of CB2 cannabinoid receptors
Chem. Phys. Lipids
Two distinctive antinociceptive systems in rats with pathological pain
Neurosci. Lett.
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
Pharmacol. Biochem. Behav.
Spinal cannabinoids are anti-allodynic in rats with persistent inflammation
Pain
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
Eur. J. Pharmacol.
Possible mechanisms of cannabinoid-induced antinociception in the spinal cord
Eur. J. Pharmacol.
Fluoride-resistant acid phosphatase-containing neurones in dorsal root ganglia are separate from those containing substance P or somatostatin
Neuroscience
Neurotoxic action of capsaicin on spinal substance P neurons
Brain Res.
Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
J. Pharmacol. Exp. Ther.
Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons
Eur. J. Neurosci.
Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons
Eur. J. Neurosci.
9-nor-9beta-Hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine
J. Pharmacol. Exp. Ther.
The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain
Br. J. Pharmacol.
The cannabinoid CB1 receptor is localised predominantly on N52 within the rat dorsal root ganglion
Soc. Neurosci. Abst.
Analgesic activity of Δ9-tetrahydrocannabinol in the rat and mouse
Psychopharmacologia
Cited by (145)
Conditioned catalepsy vs. Increase in locomotor activity induced by haloperidol
2023, Neuroscience LettersCannabinoid receptor agonists from Conus venoms alleviate pain-related behavior in rats
2021, Pharmacology Biochemistry and BehaviorSham Surgery Studies in Orthopaedic Surgery May Just Be a Sham: A Systematic Review of Randomized Placebo-Controlled Trials
2020, Arthroscopy - Journal of Arthroscopic and Related SurgeryCitation Excerpt :In white populations, the prevalence of the met-met allele is 20% to 25%.15,25-27 A large number of genetic mediators of placebo response (endocannabinoid and serotonin mediators [CB1, CB2], tryptophan hydroxylase-2 [TPH2] and 5-HTTLPR, OPRM-1 [μ opioid receptor gene], cytokines interleukin-6 and tumor necrosis factor-α) are currently known and were sought if available.13,28 Although a purpose of randomization is to mitigate the effects of selection bias, if the genetic profiles of the subjects in the analyzed studies are unknown, then it is also unknown whether the groups were significantly genetically different.